Top Markets
#1 ORDI ORDI +75.07%
#2 tomiNet tomiNet +42.74%
#3 1000SATS (Ordinals) 1000SATS (Ordinals) +37.39%
#4 SATS (Ordinals) SATS (Ordinals) +36.77%
#5 pippin pippin +33.93%
#6 Axelar Axelar +33.55%
#7 Swarms Swarms +25.58%
#8 Bio Protocol Bio Protocol +23.17%
#9 Walrus Walrus +20.25%
#10 Zerebro Zerebro +20.22%
Coin of the day
ORDI ORDI
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Kedudukan dalam Saham #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Harga Saham
$0.00047446
Modal Pasaran
$82.80
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-98.16%
Negara
FR
Perdagangan Neovacs S.A. (ALNEV)

Kategori

Healthcare
Hasil untuk Neovacs S.A. (ALNEV)
Hasil pada Dec 2024 TTM: $303.12K
Menurut laporan kewangan terkini daripada Neovacs S.A., hasil semasa syarikat (TTM) ialah $303.12K. Pada tahun 2023, syarikat memperoleh hasil sebanyak $589.67K peningkatan berbanding hasil pada tahun 2022 iaitu $1.19K. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Neovacs S.A. dari 2007 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $303.12K -20.48%
2024 $381.21K -35.35%
2023 $589.67K 49,335.08%
2022 $1.19K -95.36%
2021 $25.69K -29.17%
2020 $36.27K 0.00%
2019 0.00 -100.00%
2018 $166.63K 0.00%
2017 0.00 -100.00%
2016 $16.23K -89.89%
2015 $160.58K -6.42%
2014 $171.60K 317.73%
2013 $41.08K 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 -100.00%
2008 $75.78K -59.14%
2007 $185.43K 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 16,015,729.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 3,971,340.03%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 4,731,589.19%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 2,996,119.45%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 1,811,461.99%
NL